Background: Body mass index (BMI) is an independent prognostic factor for survival in breast cancer patients. Patients with higher BMI were found to have poorer cancer prognosis and lower survival rates. Many factors as ghrelin, adiponectin and leptin, have been implicated in obesity but their correlation with breast carcinogenesis and treatment outcome is still a debate. Objective: To identify the relation of ghrelin, adiponectin and leptin with BMI in breast cancer patients and their possible role in carcinogenesis and treatment outcome. Subjects and Methods: Sera from 80 breast cancer patients were analyzed. Ghrelin, adiponectin and leptin were assayed by commercial RIA kits, and their levels were correlated with BMI, clinicopathological parameters and relapse-free survival. The median duration of patients' follow-up was 32 months. Results: 73.7% of the cohort was overweight/ obese. Compared to breast cancer patients with normal BMI, overweight/obese patients had a significantly higher tumor size and higher histological grade. Overweight/obese patients had higher leptin and lower ghrelin and adiponectin levels. Adiponectin was lower in patients with higher tumor grade and lymph node involvement, while ghrelin decreased with increasing tumor size and histological grade. Only serum ghrelin levels were significantly correlated to better disease-free survival. Conclusion: Ghrelin, adiponectin and leptin are significant factors in controlling BMI in breast cancer patients but only ghrelin is a significant predictor of better outcome and recurrence-free survival.
INTRODUCTION
In most cases, obesity is the result of inadequate energy balance, in which the amount of energy gain exceeds the amount of energy expenditure. Body Mass Index (BMI) is usually used as an index to measure adiposity. (1) en. (4, 5) Several large-scale cohort studies such as the Cancer Prevention Study II and the study of the International Breast Cancer Study
Group have also confirmed this association between obesity and increased mortality from breast cancer. (2, 6) Given the increasing rates of obesity in women, it is critical to understand the physiological mechanisms underlying obesity and its effect on tumorigenesis. Besides excess adipose tissue, obesity has been associated with many factors including serum levels of ghrelin, adiponectin and leptin, all of which are likely to affect tumor prognosis. (2, 6) Ghrelin is a 28-amino acid orexigenic hormone produced in the stomach by the oxyntic gland that is identified as an endogenous ligand for GH secretagogues receptor. It affects energy regulation by increasing food intake and lowering the metabolic rate. It has been shown to cause a positive energy balance by decreasing fat utilization through GHindependent mechanisms. (7) Ghrelin is upregulated during starvation, cachexia, anorexia and hypoglycemia, and down-regulated during feeding and obesity. (8) It exerts its actions via activation of neuropeptide Y neurons in the hypothalamic arcuate nucleus. (9) Adiponectin, also known as Acrp30, is an adipocyte-derived protein hormone consisting of 244 amino acids which belongs to a family of adipokines. It is established that adiponectin is an insulin-sensitizing hormone with antidiabetic, anti-inflammatory and antiatherogenic properties. It promotes adipocyte differentiation, fatty acid catabolism and insulin sensitivity and is negatively correlated with obesity. (10) Leptin is one of the most studied adipo- processes including food intake regulation, immune function, and sexual development. (11) In vitro, leptin was found to induce cell proliferation in both normal and cancerous cells. (12) The study aims to evaluate the association of ghrelin, adiponectin and leptin with BMI in breast cancer patients as well as their effect on disease prognosis. All patients were treated primarily with modified radical mastectomy. The lowest level that can be detected by these assays when using a 100 µL sample size are 93 pg/mL of ghrelin, 1 ng/mL of adiponectin and 0.437 ng/mL of leptin.
SUBJECTS AND METHODS

For
In addition, 50 normal healthy individuals of matched age, menopausal status and BMI as the patients' group were included in the study as controls to confirm the normal range of the parameters included.
Ethical Considerations:
All samples were collected after the subjects' informed written consent, and confidentiality of data was insured at all stages of the study. The study was approved by the
Ethics Committee of the Medical Research
Institute.
Statistical Analysis
For variables description, the percent was 
RESULTS
The study included 80 breast cancer pa- larly. (18, 19) In accordance with that, almost three-quarters of the breast cancer cohort included in this study were overweight/obese, which reflects the high prevalence of breast cancer among these subgroups.
With respect to prognosis, however, the evidence is much less clear. Since the often cited review by Goodwin and Boyd in 1990, (20) numerous studies have been conducted in a variety of settings. While many studies concluded that obesity is indeed prognostic, many others indicated a very modest or in some cases absent influence of obesity on outcomes. (5, 6, 18) In the current study, there was no difference in DFS between various BMI subgroups of breast cancer patients. Although most studies with sufficient study population sizes have found associations between obesity and overall survival, (5, 6, 21, 23) the results vary more with respect to disease-free survival.
Some studies reported that patients who were obese and had breast cancer had a poorer disease-free survival, (22) (23) (24) while others reported no association between obesity and disease-free survival. (21, 25) This is likely a result of the definition of Z Za ah he er r e et t a al l. ., , 335
disease-free survival, the distinction between locoregional and distant metastases, and differences between study populations.
One 
Jeffery et al (30) have reported that ghrelin exerts a proliferative effect on breast cancer cell lines, which contradicts our results. Several other reports described an antiproliferative effect of ghrelin, (31) (32) which well agree with our results, where high ghrelin concentration was associated with lower tumor size and lower grade. Our results also proved ghrelin to be a good prognostic marker.
The circulating levels of adiponectin are decreased in obese individuals, (33) an observation that agreed with our findings. (36, 37) However, increased leptin levels were not associated with any of the clinicopathological parameters of cancer, did not affect DFS, although it was close to being significant (p=0.058) and it did not increase the hazard of relapse in breast cancer patients.
Obesity has been for long stated as a risk factor for breast cancer but it might not be a poor prognostic factor. However, underweight emerges as a poor prognostic factor as the underweight patients in the current study were among the first to relapse, but the number of patients in that group was so low. That strongly recommends studying the effect of being underweight on breast cancer prognosis in a larger scale study.
In conclusion, ghrelin, adiponectin and leptin are considered significant factors in controlling BMI in breast cancer patients but only ghrelin is a significant predictor of better outcome and recurrence-free survival.
